海角破解版

EasySep? Mouse CD8a Positive Selection Kit II

Immunomagnetic positive selection of mouse CD8+ cells

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep? Mouse CD8a Positive Selection Kit II

Immunomagnetic positive selection of mouse CD8+ cells

Catalog #
(Select a product)
Immunomagnetic positive selection of mouse CD8+ cells
Request Pricing Request Pricing

Product Advantages


  • Fast and easy-to-use

  • Up to 98% purity

  • No columns required

  • Isolated cells are not fluorochrome labeled

What's Included

  • EasySep? Mouse CD8a Positive Selection Kit II (Catalog #18953)
    • EasySep? Mouse CD8a Positive Selection II Component A, 0.5 mL
    • EasySep? Mouse CD8a Positive Selection II Component B, 0.5 mL
    • EasySep? Mouse FcR Blocker, 0.2 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • RoboSep? Empty Vial
  • RoboSep? Mouse CD8a Positive Selection Kit II (Catalog #18953RF)
    • EasySep? Mouse CD8a Positive Selection II Component A, 0.5 mL
    • EasySep? Mouse CD8a Positive Selection II Component B, 0.5 mL
    • EasySep? Mouse FcR Blocker, 0.2 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 mL
    • RoboSep? Empty Vial
    • RoboSep? Buffer (Catalog #20104)
    • RoboSep? Filter Tips (Catalog #20125) x 2
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Easily isolate highly purified mouse CD8a+ cells from single-cell suspensions of splenocytes or other tissue samples, using immunomagnetic positive selection, with the EasySep? Mouse CD8a Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep? positive selection procedure, desired cells are labeled with antibody complexes recognizing CD8a and magnetic particles. Labeled cells are separated using an EasySep? magnet and by simply pouring or pipetting off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation, the desired CD8a+ cells are ready for downstream applications such as flow cytometry, culture, DNA/RNA extraction.

Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? EasyEights? EasySep? Magnet (Catalog #18103)
? RoboSep?-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
T Cells, T Cells, CD8+
Species
Mouse
Sample Source
Other, Spleen
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep™ CD8a Positive Selection Profile

Figure 1. Typical EasySep™ CD8a Positive Cell Isolation Profile

Starting with mouse splenocytes, the CD8a+ cell content of the isolated fraction is typically 96.3 ± 1.4% (mean ± SD), using the purple EasySep™ magnet. In the above example, the purities of the start and final isolated fractions are 13.3% and 96.1%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
18953
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Product Name
Catalog #
18953RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (6)

LFA-1/ICAM-1 Interactions Between CD8+ and CD4+ T Cells Promote CD4+ Th1-Dominant Differentiation and CD8+ T Cell Cytotoxicity for Strong Antitumor Immunity After Cryo-Thermal Therapy Cells 2025 Apr

Abstract

CD4+ T cells have been well-regarded as “helper” cells in activating the cytotoxicity of CD8+ T cells for effective tumor eradication, while few studies have focused on whether CD8+ T cells regulate CD4+ T cells. Our previous studies provided evidence for an interaction between CD4+ and CD8+ T cells after cryo-thermal therapy, but the mechanism remains unclear, especially pertaining to how CD8+ T cells promote the Th1 differentiation of CD4+ T cells. This study revealed that activated CD4+ and CD8+ T cells are critical for CTT-induced antitumor immunity, and the interaction between activated T cells is enhanced. The reciprocal regulation of activated CD8+ and CD4+ T cells was through LFA-1/ICAM-1 interactions, in which CD8+ T cells facilitate Notch1-dependent CD4+ Th1-dominant differentiation and promote IL-2 secretion of CD4+ T cells. Meanwhile, IL-2 derived from CD4+ T cells enhances the cytotoxicity of CD8+ T cells and establishes a positive feedback loop via increasing the expression of LFA-1 and ICAM-1 on T cells. Clinical analyses further validated that LFA-1/ICAM interactions between CD4+ and CD8+ T cells are correlated with clinical outcomes. Our study extends the functions of the LFA-1/ICAM-1 adhesion pathway, indicating its novel role in the interaction of CD4+ and CD8+ T cells.
Moderate-intensity aerobic exercise training improves CD8 iScience 2024 May

Abstract

SummaryAerobic exercise training (AET) has emerged as a strategy to reduce cancer mortality, however, the mechanisms explaining AET on tumor development remain unclear. Tumors escape immune detection by generating immunosuppressive microenvironments and impaired T cell function, which is associated with T cell mitochondrial loss. AET improves mitochondrial content and function, thus we tested whether AET would modulate mitochondrial metabolism in tumor-infiltrating lymphocytes (TIL). Balb/c mice were subjected to a treadmill AET protocol prior to CT26 colon carcinoma cells injection and until tumor harvest. Tissue hypoxia, TIL infiltration and effector function, and mitochondrial content, morphology and function were evaluated. AET reduced tumor growth, improved survival, and decreased tumor hypoxia. An increased CD8+ TIL infiltration, IFN-γ and ATP production promoted by AET was correlated with reduced mitochondrial loss in these cells. Collectively, AET decreases tumor growth partially by increasing CD8+ TIL effector function through an improvement in their mitochondrial content and function. Graphical abstract Highlights?Exercise training reduces tumor growth and improves survival in colorectal cancer?Trained mice present tumors with less hypoxia and higher CD8+ T cells infiltration?The production of IFNγ by CD8+ TIL is increased in exercise-trained mice?CD8+ TIL from trained mice show higher mitochondrial density and function Natural sciences; Biological sciences; Biochemistry; Physiology; Immunology; Systems biology; Cancer systems biology
A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses iScience 2024 Feb

Abstract

SummaryMesenchymal stromal cells (MSCs) have been modified via genetic or pharmacological engineering into potent antigen-presenting cells-like capable of priming responding CD8 T cells. In this study, our screening of a variant library of Accum molecule revealed a molecule (A1) capable of eliciting antigen cross-presentation properties in MSCs. A1-reprogrammed MSCs (ARM) exhibited improved soluble antigen uptake and processing. Our comprehensive analysis, encompassing cross-presentation assays and molecular profiling, among other cellular investigations, elucidated A1’s impact on endosomal escape, reactive oxygen species production, and cytokine secretion. By evaluating ARM-based cellular vaccine in mouse models of lymphoma and melanoma, we observe significant therapeutic potency, particularly in allogeneic setting and in combination with anti-PD-1 immune checkpoint inhibitor. Overall, this study introduces a strong target for developing an antigen-adaptable vaccination platform, capable of synergizing with immune checkpoint blockers to trigger tumor regression, supporting further investigation of ARMs as an effective and versatile anti-cancer vaccine. Graphical abstract Highlights?Treatment with A1/antigen mix reprograms MSCs into antigen-presenting cells?The antigen cross-presenting ability of ARM cells require ROS and UPR?ARMs synergize with immune-checkpoint inhibitors in priming potent antitumoral activity Classification Description: Immunology; Pharmaceutical engineering; Cancer
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more